fig5
From: Tumor heterogeneity as a driver of drug resistance and its implications for personalized therapy
Figure 5. Flowchart of personalized cancer treatment guided by continuous monitoring to overcome drug resistance. For cancer patients who develop drug resistance during first-line treatments such as radiotherapy, chemotherapy, and targeted therapy, disease progression is continuously monitored and relevant research findings are integrated to precisely identify resistance mechanisms at an early stage. This approach supports the timely development and implementation of personalized therapeutic strategies. Created in BioRender. Da, E. (2026) https://BioRender.com/cg78gsu. IHC: Immunohistochemistry.
